Literature DB >> 11985514

Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis.

P T Nygårdas1, A E Hinkkanen.   

Abstract

Induction of EAE can be inhibited or repressed by administration of soluble metalloproteinase inhibitors. We studied the matrix metalloproteinase (MMP) and their tissue inhibitor (TIMP) expression pattern in experimental autoimmune encephalomyelitis (EAE) of the resistant Th2 prone BALB/c mouse, where the disease can be induced with ultrasound-emulsified antigen/adjuvant (son-ag), but not with conventional technique (syr-ag). We found highly elevated expression of MMP-8 (neutrophil collagenase) mRNA and protein in diseased son-ag challenged mice, colocalizing to neutrophil infiltrates found in brain and extensively in the spinal cord submeningeal space. MMP-8 expression has not been found previously in sensitive mouse strains. The infiltrates stained positive also for MMP-9 protein, and brain homogenates from corresponding mice showed MMP-9 activity during overt disease (days 12-16 post-immunization). TIMP-1 gene expression could be detected in CNS samples from diseased son-ag challenged mice but not in syr-ag or control mice, and the TIMP-1 protein colocalized with GFAP-staining. In contrast, in syr-ag mice both TIMP-2 and TIMP-3 gene expression in the spinal cords was elevated. The results show that sonication, but not extrusion, creates an adjuvant formula potent in activating the matrix metalloproteinase cascade similar to sensitive mouse strains, strongly implicating their role in EAE induction in this Th2 prone strain. The study provides the basis for establishment of MMP-specific therapy in this model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985514      PMCID: PMC1906387          DOI: 10.1046/j.1365-2249.2002.01855.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Matrix metalloproteinases degrade myelin basic protein.

Authors:  S Chandler; R Coates; A Gearing; J Lury; G Wells; E Bone
Journal:  Neurosci Lett       Date:  1995-12-15       Impact factor: 3.046

Review 2.  Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity.

Authors:  R M Zinkernagel; S Ehl; P Aichele; S Oehen; T Kündig; H Hengartner
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

3.  Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions.

Authors:  A Maeda; R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

4.  Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard.

Authors:  G M Wells; G Catlin; J A Cossins; M Mangan; G A Ward; K M Miller; J M Clements
Journal:  Glia       Date:  1996-12       Impact factor: 7.452

5.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.

Authors:  J M Clements; J A Cossins; G M Wells; D J Corkill; K Helfrich; L M Wood; R Pigott; G Stabler; G A Ward; A J Gearing; K M Miller
Journal:  J Neuroimmunol       Date:  1997-04       Impact factor: 3.478

6.  The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution.

Authors:  M L Cuzner; D Gveric; C Strand; A J Loughlin; L Paemen; G Opdenakker; J Newcombe
Journal:  J Neuropathol Exp Neurol       Date:  1996-12       Impact factor: 3.685

7.  Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases.

Authors:  M K Matyszak; V H Perry
Journal:  J Neuroimmunol       Date:  1996-09       Impact factor: 3.478

8.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790.

Authors:  A K Hewson; T Smith; J P Leonard; M L Cuzner
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

Review 9.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

10.  Physical state of the neuroantigen in adjuvant emulsions determines encephalitogenic status in the BALB/c mouse.

Authors:  J A Määttä; J P Erälinna; M Röyttä; A A Salmi; A E Hinkkanen
Journal:  J Immunol Methods       Date:  1996-03-28       Impact factor: 2.303

View more
  25 in total

1.  Molecular cloning and characterization of a matrix metalloproteinase, from Caenorhabditis elegans: employed to identify homologous protein from Angiostrongylus cantonensis.

Authors:  Rui Sun; Zheng-yu Li; Han-jiang He; Jie Wei; Juan Wang; Qi-xian Zhang; Jia Zhao; Xi-mei Zhan; Zhong-dao Wu
Journal:  Parasitol Res       Date:  2011-12-14       Impact factor: 2.289

2.  Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice.

Authors:  Stephen J Crocker; Jason K Whitmire; Ricardo F Frausto; Parntip Chertboonmuang; Paul D Soloway; J Lindsay Whitton; Iain L Campbell
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

4.  Multiple expression of matrix metalloproteinases in murine neurocysticercosis: Implications for leukocyte migration through multiple central nervous system barriers.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

Review 5.  The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction.

Authors:  Britta Engelhardt; Lydia Sorokin
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

6.  Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination.

Authors:  Evelien Houben; Kris Janssens; Doryssa Hermans; Jennifer Vandooren; Chris Van den Haute; Melissa Schepers; Tim Vanmierlo; Ivo Lambrichts; Jack van Horssen; Veerle Baekelandt; Ghislain Opdenakker; Wia Baron; Bieke Broux; Helena Slaets; Niels Hellings
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

7.  Matrix Metalloproteinase-8 Inhibition Prevents Disruption of Blood-Spinal Cord Barrier and Attenuates Inflammation in Rat Model of Spinal Cord Injury.

Authors:  Hemant Kumar; Min-Jae Jo; Hyemin Choi; Manjunatha S Muttigi; Seil Shon; Byung-Joo Kim; Soo-Hong Lee; In-Bo Han
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 8.  Glial development: the crossroads of regeneration and repair in the CNS.

Authors:  Vittorio Gallo; Benjamin Deneen
Journal:  Neuron       Date:  2014-07-16       Impact factor: 17.173

9.  Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.

Authors:  Kiran Gona; Jakub Toczek; Yunpeng Ye; Nowshin Sanzida; Arvene Golbazi; Parnaz Boodagh; Mani Salarian; Jae-Joon Jung; Saranya Rajendran; Gunjan Kukreja; Terence L Wu; Laurent Devel; Mehran M Sadeghi
Journal:  J Med Chem       Date:  2020-11-18       Impact factor: 7.446

10.  Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis.

Authors:  Athena M Soulika; Eunyoung Lee; Erica McCauley; Laird Miers; Peter Bannerman; David Pleasure
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.